SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?


To: Bill Harmond who wrote (98223)3/31/2000 8:58:00 PM
From: Glenn D. Rudolph  Respond to of 164684
 
From The Street.com

"
When Wall Street filled out its last ticket, turned off the screen and
pushed its chair back under the desk on Friday, it was in no mood
for reflecting on the week that had been, with its crushing selling in
anything tech.

It was in no mood for thinking about how fund managers had raced
to get recently fallen highfliers off their books before quarter end,
nor was it in the mood for trying to figure out what role margin calls
may have played in the downturn.

The only thing it was in the mood for, really, was a good stiff drink.

And there we'll leave it, sitting at the bar at the Whitehorse Tavern,
playing "Lyin' Eyes" over and over again on the jukebox and
waiting for its friends from Prudential, who promised they would
show up.

The coming week will probably be better. Many weak holders --
investors who were piling into the market for a quick buck -- have
been shaken out, and all those fund managers who were busy
selling to spruce up their end-of-quarter statements will be looking
to put new cash to work.

But though things may settle, it is probably a mistake to think that
things will go back to the way they were before. The latest
shakeout suggests that the days of indiscriminate gains in hot
sectors are probably over. The market's focus has changed.

Thursday, when the Nasdaq Composite fell 4% while the New
York Stock Exchange Composite only slipped 0.6%, a crucial
day for John Bollinger, president of EquityTrader.com.

"There are two ways a market can go down," he explained.
"Money can be withdrawn or money can be rotated. Money came
out of the Nasdaq stocks, but it didn't go to the sidelines. That
rotation was enough to prevent the decline from spreading beyond
the Nasdaq."

Bollinger laid a lot of the blame for the selloff on portfolio managers
who, he said "didn't want to show how much they relied on
high-tech and volatile issues, so they bought quality growth." He
reckons that move into quality growth -- companies that are
growing quickly, but in a more quantifiable manner (e.g. they have
earnings) -- will probably persist.

Bollinger is not alone in thinking this.

"You basically had a market that has gone through kind of a
blowoff in tech stocks," said Rao Chalasani, chief investment
strategist at First Union Securities. "At the same time, you're
looking at the discovery of the Old Economy stocks."

Chalasani thinks there are some choppy days ahead, but if the
Nasdaq can hold recent levels it can stabilize and move up -- but
not in the same manner that it did in the fourth quarter and early
this year. "If the Nasdaq makes a new high, it will be based on
higher quality stocks going up, not the whole market going up," he
said. "

I found this a little vague. Are they inferring that stocks such as INTC, CSCO, MSFT, etc. will continue up but firms such as CMRC, VERT, ARBA, VIGN, PHCM, etc. will not?



To: Bill Harmond who wrote (98223)4/1/2000 4:22:00 AM
From: Sam Citron  Read Replies (1) | Respond to of 164684
 
>>NPSP's two drugs are each potentially huge.

NPSP has at least 11 drugs in development.
npsp.com

Which two do you think have the most potential?

Do you think enough speculative wind has come out of the biotech sector that it is now safe to enter?